Newron Pharmaceuticals SpA (NWRN)

Currency in CHF
7.61
+0.05(+0.66%)
Delayed Data·
NWRN Scorecard
Full Analysis
RSI suggests the stock is in overbought territory
NWRN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.397.65
52 wk Range
5.2011.00
Key Statistics
Bid/Ask
7.60 / 7.65
Prev. Close
7.56
Open
7.56
Day's Range
7.39-7.65
52 wk Range
5.2-11
Volume
5.17K
Average Volume (3m)
38.23K
1-Year Change
4.56%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NWRN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
18.24
Upside
+139.67%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Newron Pharmaceuticals SpA Company Profile

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.

Compare NWRN to Peers and Sector

Metrics to compare
NWRN
Peers
Sector
Relationship
P/E Ratio
9.9x−1.2x−0.5x
PEG Ratio
0.050.150.00
Price/Book
107.5x0.1x2.6x
Price / LTM Sales
3.0x3.0x3.3x
Upside (Analyst Target)
163.5%91.2%40.3%
Fair Value Upside
Unlock3.6%4.7%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 18.24
(+139.67% Upside)

Earnings

Latest Release
Mar 31, 2025
EPS / Forecast
1.12 / -0.49
Revenue / Forecast
47.98M / 3.40M
EPS Revisions
Last 90 days

NWRN Income Statement

People Also Watch

8.189
BMPS
+0.12%
34.0000
GASI
+1.52%
8.386
STLAM
+1.33%
898.60
SLHN
+0.94%
28.120
KURN
+5.79%

FAQ

What Stock Exchange Does Newron Pharmaceuticals Trade On?

Newron Pharmaceuticals is listed and trades on the Switzerland Stock Exchange stock exchange.

What Is the Stock Symbol for Newron Pharmaceuticals?

The stock symbol for Newron Pharmaceuticals is "NWRN."

What Is the Newron Pharmaceuticals Market Cap?

As of today, Newron Pharmaceuticals market cap is 150.91M.

What Is Newron Pharmaceuticals's Earnings Per Share (TTM)?

The Newron Pharmaceuticals EPS (TTM) is 0.85.

From a Technical Analysis Perspective, Is NWRN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Newron Pharmaceuticals Stock Split?

Newron Pharmaceuticals has split 0 times.

How Many Employees Does Newron Pharmaceuticals Have?

Newron Pharmaceuticals has 22 employees.

What is the current trading status of Newron Pharmaceuticals (NWRN)?

As of 14 Aug 2025, Newron Pharmaceuticals (NWRN) is trading at a price of 7.61, with a previous close of 7.56. The stock has fluctuated within a day range of 7.39 to 7.65, while its 52-week range spans from 5.20 to 11.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.